Innovative ETFs ChannelPfizer’s COVID-19 Pill Has Mixed Results for Healthcare ETFsBy Max ChenNovember 5, 2021
Innovative ETFs ChannelA Biotech ETF to Track Nasdaq’s Industry-Setting BenchmarkBy Max ChenJune 30, 2021
Beyond Basic Beta ChannelArtificial Intelligence Set to Transform the Pharmaceutical IndustryBy Ben HernandezJune 1, 2021
Beyond Basic Beta ChannelPharma Goes Beyond the Vaccine. ‘PPH’ on the Verge of More AdvancesBy Ben HernandezMarch 4, 2021
Innovative ETFs ChannelConsider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021By Max ChenDecember 31, 2020
Beyond Basic Beta ChannelAssessing Political Outcomes for Pharmaceuticals ETFsBy Tom LydonJuly 21, 2020
Beyond Basic Beta ChannelExpect Pharmaceuticals M&A Activity to Rebound After COVID-19 EasesBy Tom LydonApril 17, 2020
WebcastsAn Active ETF Approach to Target Innovations in Next Generation SequencingBy Max ChenNovember 14, 2019
Beyond Basic Beta Channel8 ETFs to Capture Opportunities in Healthcare SectorBy Max ChenAugust 22, 2019
Innovative ETFs ChannelBiotech ETFs Strengthen After Judge Blocks Trump’s Drug Pricing RuleBy Max ChenJuly 9, 2019
Innovative ETFs ChannelAbbVie, Allergan Deal Puts Spotlight on Pharmaceutical ETFsBy Max ChenJune 25, 2019
Innovative ETFs ChannelPharmaceutical ETFs Break Out on Horizon Pharma’s Positive Drug ResultsBy Max ChenFebruary 28, 2019
Core Equity ChannelHealthcare ETFs Slip After Abbot Lab’s Revenue Miss, Weak OutlookBy Max ChenJanuary 23, 2019
